| nucleotide binding fold | Protein motif consisting of a fold or pocket with certain conserved residues, required for the binding of nucleotides. (18 Nov 1997) |
|---|---|
| DNA binding protein | <molecular biology> Proteins that interact with DNA, typically to pack or modify the DNA for example histones or to regulate gene expression, transcription factors. Among those proteins that recognise specific DNA sequences, there are a number of characteristic conserved motifs believed to be essential for specificity. (18 Nov 1997) |
| DNA-binding protein, cyclic AMP-responsive | A protein that has been shown to function as a calcium regulated transcription factor as well as a substrate for depolarisation-activated calcium calmodulin-dependent protein kinases I and II. This protein functions to integrate both calcium and camp signals. (12 Dec 1998) |
| DNA-binding proteins | Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. (12 Dec 1998) |
| insulin binding | When insulin attaches itself to something else. This can occur in two ways. First, when a cell needs energy, insulin can bind with the outer part of the cell. The cell then can bring glucose (sugar) inside and use it for energy. With the help of insulin, the cell can do its work very well and very quickly. But sometimes the body acts against itself. In this second case, the insulin binds with antibodies. If the insulin is an injected form of insulin and not made by the body, the body sees the insulin as an outside or foreign substance. When the injected insulin binds with the antibodies, it does not work as well as when it binds directly to the cell. (09 Oct 1997) |
| insulin-like growth-factor binding protein 1 | One of the six homologous proteins that specifically bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions. The function of this protein is not completely defined. However, several studies demonstrate that it inhibits igf binding to cell surface receptors and thereby inhibits igf-mediated mitogenic and cell metabolic actions. (proc soc exp biol med 1993;204(1):4-29) (12 Dec 1998) |
| insulin-like growth factor-binding protein 2 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin-like growth factor binding protein 3 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin like growth-factor-binding protein 4 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin-like growth-factor-binding-protein 5 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin-like-growth-factor-binding protein 6 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin-like growth-factor-binding proteins | A family of soluble proteins that bind insulin-like growth factors and modulate their biological actions at the cellular level. (int j gynaecol obstet 1992;39(1):3-9) (12 Dec 1998) |
| intestinal calcium-binding protein | <protein> Calcium-binding proteins containing the EF hand motif, induced by vitamin D3. (18 Nov 1997) |
| iron-binding capacity | The capacity of iron-binding protein in serum (transferrin) to bind serum iron. (05 Mar 2000) |
| octamer binding protein | <protein> Transcription factor that binds to the octamer motif. Examples: mammalian proteins Oct 1, Oct 2. (18 Nov 1997) |